Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Toronto

$105,000.00

The Effect of Adjunctive Semaglutide Treatment on Reward Based Decision Making in Patients with Major Depressive Disorder

EF 2021-22

Résumé
Depression and metabolic disorders, such as obesity, are often co-occuring disorders. Multiple lines of evidence suggest that changes in reward behaviour and cognitive functioning may be responsible for the mechanisms underlying the relationship between depression and metabolic disorders such as obesity. However, there remains a lack of studies that have evaluated the deficits in reward and cognitive functioning in populations with depression. Preliminary findings suggest that the glucagon-like peptide 1 (GLP-1) receptor, an endogenous gastrointestinal hormone, may influence reward and cognitive processing. GLP-1 receptors have been shown to directly influence hedonic reward processes and feeding behaviours, as well as general cognitive processes (e.g., working memory). Semaglutide is a recently approved GLP-1R agonist, which is well tolerated in both healthy controls and clinical populations (e.g. psychiatric populations), with a low rate of discontinuation. The role of the GLP-1 receptor in cognitive and reward-based decision making, and the ability of semaglutide to modulate the GLP-1 receptor presents a promising treatment option for people with MDD. Improvements in reward and cognition can lead to increased interest and pleasure in daily activities. This is an important factor for improving an individual's quality of life. Our study will aim to investigate the treatment efficacy of semaglutide in 60 people with MDD by monitoring depressive symptoms, executive functioning, working memory and motivation and interest in reward over a 16 week period. We believe semaglutide will improve interest or pleasure for seeking reward, as well as general cognitive processes (e.g., working memory and executive functioning) in people with depression and obesity. As such, the GLP-1 receptor can be an important treatment target for improving these common symptoms experienced by populations with depression and obesity.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
458352
Name
Gill Hartej
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Clinical
Prcname2
Doctoral Research Awards - A
Projecttitle
The Effect of Adjunctive Semaglutide Treatment on Reward Based Decision Making in Patients with Major Depressive Disorder
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Cognition; Depression; Metabolic Disorders; Mood And Anxiety Disorders; Obesity; Reward
Abstract
Depression and metabolic disorders, such as obesity, are often co-occuring disorders. Multiple lines of evidence suggest that changes in reward behaviour and cognitive functioning may be responsible for the mechanisms underlying the relationship between depression and metabolic disorders such as obesity. However, there remains a lack of studies that have evaluated the deficits in reward and cognitive functioning in populations with depression. Preliminary findings suggest that the glucagon-like peptide 1 (GLP-1) receptor, an endogenous gastrointestinal hormone, may influence reward and cognitive processing. GLP-1 receptors have been shown to directly influence hedonic reward processes and feeding behaviours, as well as general cognitive processes (e.g., working memory). Semaglutide is a recently approved GLP-1R agonist, which is well tolerated in both healthy controls and clinical populations (e.g. psychiatric populations), with a low rate of discontinuation. The role of the GLP-1 receptor in cognitive and reward-based decision making, and the ability of semaglutide to modulate the GLP-1 receptor presents a promising treatment option for people with MDD. Improvements in reward and cognition can lead to increased interest and pleasure in daily activities. This is an important factor for improving an individual's quality of life. Our study will aim to investigate the treatment efficacy of semaglutide in 60 people with MDD by monitoring depressive symptoms, executive functioning, working memory and motivation and interest in reward over a 16 week period. We believe semaglutide will improve interest or pleasure for seeking reward, as well as general cognitive processes (e.g., working memory and executive functioning) in people with depression and obesity. As such, the GLP-1 receptor can be an important treatment target for improving these common symptoms experienced by populations with depression and obesity.
Competitiondate
202111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Gill, Hartej
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~